LFBC(SZ:002513)2021-04-19 16:00Financial Performance - The company's revenue for Q1 2021 was ¥333,685,157.13, representing a 40.28% increase compared to ¥237,864,645.78 in the same period last year[8]. - Net profit attributable to shareholders was ¥1,235,069.65, a significant turnaround from a loss of ¥15,414,150.34 in the previous year, marking an increase of 108.01%[8]. - Basic earnings per share rose to ¥0.004 from a loss of ¥0.05, indicating an increase of 108.00%[8]. - The company reported a total profit of ¥1,522,672.21 for Q1 2021, compared to a total loss of ¥21,043,995.69 in the same period last year[39]. - The net profit for the first quarter was CNY 15 million, which is a 10% increase compared to the same period last year[18]. Cash Flow - The net cash flow from operating activities improved to ¥16,943,743.63, compared to a negative cash flow of ¥43,166,633.92 in the same period last year, reflecting a 139.25% increase[8]. - Operating cash inflow totaled CNY 372,491,238.24, up from CNY 259,437,054.05 in the previous period, representing an increase of approximately 43.5%[47]. - Cash and cash equivalents at the end of the period were CNY 189,769,647.30, down from CNY 226,794,968.20 at the beginning of the period, reflecting a decrease of 16.4%[48]. - Cash inflow from financing activities was CNY 69,000,000.00, a decrease of 25.8% compared to CNY 93,000,000.00 in the previous period[48]. - Cash outflow from financing activities totaled CNY 94,245,287.16, down from CNY 115,815,803.12, indicating a reduction of 18.6%[48]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,297,229,128.34, a slight decrease of 0.60% from ¥2,311,049,219.02 at the end of the previous year[8]. - Total current assets decreased from 822,936,819.64 to 813,490,818.33, a decline of approximately 1.8%[29]. - Total liabilities decreased from 1,151,139,145.31 to 1,136,645,049.91, a reduction of approximately 1.3%[31]. - Total equity increased from 1,159,910,073.71 to 1,160,584,078.43, a growth of about 0.06%[32]. - Total non-current assets slightly decreased from 1,488,112,399.38 to 1,483,738,310.01, a decline of about 0.3%[30]. Shareholder Information - The total number of shareholders at the end of the reporting period was 11,192[11]. - Jiangsu Suhua Group Co., Ltd. was the largest shareholder, holding 20.09% of the shares, equivalent to 68,334,137 shares[11]. - The company did not engage in any repurchase transactions among its top shareholders during the reporting period[12]. Operational Highlights - Operating revenue grew by 40.28% year-on-year, primarily driven by increased product sales[15]. - Operating costs rose by 49.31% year-on-year, attributed to the growth in product sales[15]. - Sales expenses decreased by 86.92% year-on-year, mainly because Ark Pharmaceutical is no longer included in the company's consolidated financial statements[15]. - Research and development expenses fell by 39.45% year-on-year, due to a reduction in R&D projects[15]. - Cash received from sales of goods and services increased by 45.35% year-on-year, reflecting higher operating revenue[15]. Strategic Initiatives - The company plans to invest CNY 50 million in new product development and technology research in the upcoming quarters[18]. - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 15% market share within the next two years[18]. - The company plans to continue focusing on market expansion and new product development to drive future growth[38]. Compliance and Governance - There are no reported securities or derivative investments during the reporting period, indicating a conservative investment approach[19][20]. - No significant related party transactions were reported, ensuring transparency and compliance with regulatory standards[18]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or their affiliates during the reporting period[22]. - There were no violations regarding external guarantees, maintaining a strong financial position[22].